| Literature DB >> 35052891 |
Mathieu Nicolas1,2, Bruno Beito3, Marta Oliveira3, Maria Tudela Martins3, Bruno Gallas2, Michèle Salmain4, Souhir Boujday1, Vincent Humblot1,5.
Abstract
Nosocomial and medical device-induced biofilm infections affect millions of lives and urgently require innovative preventive approaches. These pathologies have led to the development of numerous antimicrobial strategies, an emergent topic involving both natural and synthetic routes, among which some are currently under testing for clinical approval and use. Antimicrobial peptides (AMPs) are ideal candidates for this fight. Therefore, the strategies involving surface functionalization with AMPs to prevent bacterial attachment/biofilms formation have experienced a tremendous development over the last decade. In this review, we describe the different mechanisms of action by which AMPs prevent bacterial adhesion and/or biofilm formation to better address their potential as anti-infective agents. We additionally analyze AMP immobilization techniques on a variety of materials, with a focus on biomedical applications. Furthermore, we summarize the advances made to date regarding the immobilization strategies of AMPs on various surfaces and their ability to prevent the adhesion of various microorganisms. Progress toward the clinical approval of AMPs in antibiotherapy is also reviewed.Entities:
Keywords: AMP; antimicrobial; biofilms; biofunctionalization; immobilization; peptide
Year: 2021 PMID: 35052891 PMCID: PMC8772980 DOI: 10.3390/antibiotics11010013
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Scanning electron microscopy image of P. aeruginosa PA14, cultured as a pellicle. Reproduced from [24]. Copyright © 2011 Franklin et al.
Figure 2Five stages of biofilm development. Reproduced from [29]. Copyright © 2018 Abu Bakar et al. Reproduced by permission from Perfectus Biomed Limited. http://perfectusbiomed.com/cbe-meeting-anti-biofilm-technologies/.
Figure 3Antimicrobial peptide mechanisms of action. (A). The barrel-stave model. (B) The carpet model. (C) The toroidal or wormhole pore model. Adapted from [48]. Copyright © 2012 Elsevier Ltd. All rights reserved.
Figure 4Three-dimensional (3D) structures of representative antimicrobial peptides. (A) α-helical Scheme 37. (PDB code: 2K6O); (B) β-sheet structure of plant kalata B1 (PDB code: 1NB1); (C) αβ structure of human β-defensin-1 HBD-1 (PDB code: 1IJV); (D) non-αβ structure of cattle indolicidin (PDB code: 1G89).
AMPs in clinical trials (phase I-III) and preclinical trials (2019). Data collected from ref. [53,55,59,60,61,62].
| AMP | AMP Source | Target a | Phase | Company |
|---|---|---|---|---|
| EA-230 | hCG derivative | Sepsis and renal failure | II | Exponential Biotherapies |
| protection | ||||
| CZEN-002 | α-MSH derivative | Anti-fungal | II | Zengen |
| XMP-629 | BPI derivative | Impetigo and acne rosacea | III | Xoma Ltd. |
| Neuprex(rBPI21) | BPR derivative | Pediatric meningococcemia | III | Xoma Ltd. |
| Delmitide(RDP58) | HLA class I derivative | Inflammatory bowel disease | II | Genzyme |
| Ghrelin | Endogenous HDP | Chronic respiratory failure | II | University of Miyazaki; Papworth Hospital |
| NVB-302 | Lantibiotic |
| I | Novacta |
| hLF1-11 | Lactoferricin derivative | MRSA, | I/II | AM-Pharma |
| Wap-8294A2 (Lotilibcin) | G(+) bacteria(VRE, MRSA) | I/II | aRigen | |
| DPK-060 | Kininogen derivative | Acute external otitis | II | ProMore Pharma |
| PXL01 | Lactoferrin analog | Postsurgical adhesions | III | ProMore Pharma |
| PAC113 | Histatin 5 analog | Oral candidiasis | II | Pacgen Biopharmaceuticals |
| POL7080 | Protegrin analog |
| III | Polyphor Ltd. |
| OP-145 | LL-37 derivative | Chronic middle ear infection | II | Dr. Reddy’s Research |
| LL-37 | Human cathelicidin | Leg ulcer | II | ProMore Pharma |
| Novexatin (NP213) | Cyclic cationic peptide | Fungal nail infection | II | Novabiotics |
| Iseganan (IB-367) | Protegrin analog | Pneumonia, stomatitis | III | IntraBiotics Pharmaceuticals |
| Pexiganan (MSI-78) | Magainin analog | Diabetic foot ulcers | III | Dipexium Pharmaceuticals |
| Omiganan (CLS001) | Indolicidin derivative | Rosacea | III | Cutanea Life Sciences |
| Surotomycin | Cyclic lipopeptide | III | Cubist Pharmaceuticals/Merck | |
| Ramoplanin (NTI-851) | G(+) (VRE, | III | Nano-therapeutics | |
| Friulimicin B | Cyclic lipopeptide | Pneumonia, MRSA | I | MerLion Pharmaceuticals |
| MU1140 | Lantibiotic | G(+) bacteria (MRSA, | P | Oragenics |
| HB1275 | Lipopeptide | Fungal skin infections | P | Helix Biomedix |
| HB1345 | Lipopeptide | Skin infections, acne | P | Helix Biomedix |
| Arenicin (AP139) |
| G(−) bacteria, UTI | P | Adenium Biotech |
| AP114 | Arenicin analog |
| P | Adenium Biotech |
| AP138 | Arenicin analog | MRSA | P | Adenium Biotech |
| Novamycin (NP339) | Poly-arginine cationic peptide | Fungal infections | P | Novabiotics |
| Avidocin and Purocin | Modified bacteriocin | G(−) bacteria | P | Pylum Biosciences |
a G(+), Gram positive; G(−), Gram negative; MRSA, methicillin-resistant S. aureus; VRE, vancomycin-resistant Enterococci; UTI, urinary tract infection; P, preclinical.
Overview of AMP immobilization on solid surfaces and their antimicrobial activity.
| AMP | Substratum | Immobilization Strategy | Studied Microorganisms | Reference |
|---|---|---|---|---|
| Magainin I | Gold surface | Self-assembled monolayer | Humblot et al., (2009) [ | |
| LL37 | Titanium surface | Site-specific conjugation via amine-reactive NHS and thiol-reactive maleimide moieties |
| Gabriel et al., (2006) [ |
| HHC36 | Titanium surface | CuAAC click chemistry: Titanium silanized with APTS and peptide modified with PEG | Chen et al., (2019) [ | |
| Tet-213 | Titanium slide | Tethering on copolymer brushes of N,N-dimethylacrylamide/N-(3-aminopropyl)-methacrylamide hydrochloride |
| Gao et al., (2011) [ |
| Tet-213, 1010cys, Tet-20, Tet-21, Tet-26, HH2, MXX226 | Titanium slide | Covalently grafted hydrophilic polymer brushes conjugated with peptides | Gao et al., (2011) [ | |
| Magainin I | Silicon wafer | Tethering on copolymer brushes of 2-(2 methoxyethoxy) ethylmethacrylate/hydroxyl-terminated oligo (ethylene glycol) Poly(MOE2MA-co-HOEGMA) | Glinel et al., (2009) [ | |
| CW11 | Polydimethylsiloxane (PDMS) | Cross-linking of peptides to allylglycidyl ether modified PDMS surface (PDMS-AGE-PEG) via Sulfhydryl Chemistry | Lim et al., (2013) [ | |
| RK1 and RK2 | Silicone urinary catheter and Polydimethylsiloxane (PDMS) | Cross-linking of peptides to allylglycidyl ether modified PDMS surface (PDMS-AGE) | Li et al., (2014) [ | |
| Temporin-SHa | Titanium surface | Covalent immobilization on Si-O-Ti groups | Masurier et al., (2018) [ | |
| 122 variant peptides of 2 starting sequences: Bac2A and Indolicidin | Cellulose support | Cellulose-amino-hydroxypropyl ether (CAPE) linker chemistry; or directly synthetized onto a bifunctional resin; or directly bound to the microtiter plate via biotin-streptavidin interaction | Hilpert et al., (2009) [ | |
| TBKKG6A and lasioglossin-III | Cellulose support | cysteine-cellulose conjugate coupled to obtaining thioester peptides either on the C-terminal or the N-terminal part of the molecules |
| Sperandeo et al., (2020) [ |
| Antibacterial hybrid peptide | Silicone catheter | Covalent immobilization on silanol groups | Pinese et al., (2016) [ | |
| Bioactive peptides | Silicone dressing | Covalent immobilization on silanol groups | Studies of peptides bioactivity | Pinese et al., (2017) [ |
| Protamine, a mixture of Protamine and Melittin and Melimine | Commercial contact lens (Etafilcon-A) | Physical adsorption and covalent attachment via EDC | Willcox et al., (2008) [ | |
| hLF1-11 | Titanium surface silanized with CPTES or APTES | Peptide physical adsorption and covalent binding with CPTES or APTES | Godoy-Gallardo et al., (2014) [ | |
| Dhvar5 | Titanium and gold substrates | Physical adsorption and covalent binding with chitosan films, EDC-NHS chemistry and introduction of amino acids spacers |
| Costa et al., (2015) [ |
| Defensin from | Multilayer polyelectrolyte films of PEI-(PSS-PAH)2-(PGA-PLL)n | Layer-by-layer | Etienne et al., (2004) [ | |
| Gramicidin A complexed with a non-denaturing anionic amphiphilic polysaccharide | Multilayer polyelectrolyte films of PEI and PLL | Layer-by-layer |
| Guyomard et al., (2008) [ |
| Ponericin G1 | Silicone substrate | Layer-by-layer |
| Shukla et al., (2010) [ |
| Magainin II | Stainless Steel | Modification of peptide with dopamine, direct grafting via catechol groups | Cao et al., (2020) [ | |
| HHC-36 | PU substrates | Zhang et al. 2019 [ | ||
| MSI-78A | Au | SAMS EG4 thiols-biotin-neutravidin-maleimide |
| Parreira et al. 2019 [ |
| MSI-78 | CaFé | Silica layer + maleimide |
| Xiao et al. 2018 [ |
Figure 5(A) Scheme of magainin I immobilization. Step 1: formation of SAM of MUA on gold, Au-MUA; step 2: esterification of the COOH function of MUA by NHS/EDC, Au–MUAact; step 3: covalent binding of magainin I, Au–MUA–MAG (B) AFM images of gold samples Au–MUA (a,c) and Au–MUA–MAG (b,d) obtained after 30 min and 3 h, respectively, of contact with a Listeria ivanovii bacterial suspension at 1.5 × 106 cfu/mL at 37 °C; imaging conditions: 50 µm × 50 µm, 512 lines, 2 Hz, tapping mode. Reproduced from [71]. Copyright © 2009 Elsevier Ltd. All rights reserved.
Figure 6Random and site-specific strategies for coupling cathelicidin (LL-37) to titanium surface. Mal = maleimide; prop = propyl; PEG = poly(ethylene glycol).
Figure 7Fluorescence detection of bactericidal activity as a function of LL-37 AMP orientation and distance with respect to the surface. Reproduced with permission from [72]. Copyright 2006 American Chemical Society.
Figure 8Schematic illustration of the CuAAC click chemistry on the titanium surface. Reproduced with permission from [73]. Copyright 2019 American Chemical Society.
Figure 9Synthetic route for copolymer brushes generation on titanium surface.
Figure 10Different steps of functionalization to study the influence of brush properties of polymers on AMPs activity. Adapted with permission from [74]. Copyright 2011 American Chemical Society.
Figure 11Antimicrobial activity of surface-immobilized peptides. Inhibition of luminescence of P. Aeruginosa upon incubation with titanium slides modified with peptide immobilized copolymer brush (surface area: 1 cm2); inhibition of luminescence is taken as a measure of antimicrobial activity. Ti-slides and polydimethylacrylamide (PDMA) brush coated Ti-slides (neutral brushes) were used as controls. Reproduced with permission from [75]. Copyright 2011 American Chemical Society.
Figure 12Oriented grafting of MAG-Cys derivative on poly(MOE2MA-co-HOEGMA) brushes via heterobifunctional crosslinker PMPI. Adapted with permission from [76]. Copyright 2009 American Chemical Society.
Figure 13SEM images of P. aeruginosa in contact with cellulose membrane: (A) without peptide; (B) with an active tethered peptide. Reproduced from [80]. Copyright © 2009 Elsevier Ltd. All rights reserved.
Figure 14Summary of the Strategy used to covalently attach thioester peptides to cysteine-modified cellulose surfaces.
Figure 15Example of site-specific grafting of hybrid temporin 1 on titanium surfaces. Temporins were modified at their C-ter end by a silanol group that enables the direct grafting onto TEOS precursor. Reproduced from [79]. Copyright © The Royal Society of Chemistry 2018.
Figure 16Grafting of AMP on activated silicone catheter (top) and on activated silicone dressing (bottom). For both strategies, the commercial silicone is activated by plasma before direct grafting of the modified peptide by a silanol group. Reproduced from [82,83]. Copyright © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. Copyright © 2017 Elsevier Ltd. All rights reserved.
Figure 17In vivo study. (A) Pictures of wounds inflicted on the back of a pig (at days 0, 3 and 5); (B) percentage of recovery of the scars (peptide-treated vs. non-treated dressings). Reproduced from [83]. Copyright © 2017 Elsevier Ltd. All rights reserved. Statistically significant differences vs. control samples are indicated with an * (p < 0.05).
Figure 18Transmission electron microscopy (a) Pseudomonas aeruginosa strain 6294; (b) P. aeruginosa Scheme 6294. exposed to melimine. Reproduced from [84]. © 2008 Willcox et al. J. Appl. Microbiol. © 2008 The Society for Applied Microbiology.
Figure 19Functionalization strategies to anchor the hLf1-11 peptide to titanium: physical adsorption and covalent binding with CPTES or APTES. Adapted from [85]. Copyright © 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
Figure 20Bacterial adhesion of S. sanguinis (a) and L. salivarius (b) to titanium samples after 2 h of incubation at 37 °C. Statistically significant differences vs. control samples are indicated with an * (p < 0.05). Reproduced from [85]. Copyright © 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
Figure 21(a) Chitosan modification with N-acetyl cysteine (NAC); (b) Dhvar5 peptide derived in Table 2 peptides by disulfide bridge formation (a control surface, Ch Dhvar5 ads, was used where peptide was only physisorbed, not covalently bound). (c) Dhvar5 peptide immobilization strategy. Reproduced from [98]. Copyright © 2015 Elsevier Ltd. All rights reserved.
Figure 22Scheme of polyelectrolyte multilayer film (A) and defensin insertion (B). Adsorption is obtained by adding a layer of the opposite charge; the peptide is embedded under another polyelectrolyte layer. Reproduced from [86]. Copyright © 2004 American Society for Microbiology.
Figure 23Process used for immobilization of Gramicidin A. Reproduced from [87]. Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Figure 24Process used for the immobilization of ponericin G1 embedded with the LbL structure (A) structures of all polyelectrolytes used in the LbL process. (B) schematic protocol of LbL elaboration and (C) Schematic expected structure of the final LbL film. Reproduced from [88]. Copyright © 2009 Elsevier Ltd. All rights reserved.